Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Executive Summary
Known for his thought-provoking views on transforming Indian pharmaceutical research, Barbhaiya says multinational companies should shed conventional methods when teaming up with Indian companies for true innovation to thrive.
You may also be interested in...
Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
MUMBAI - Past debacles in the glucokinase class of compounds notwithstanding, India's leading research firm Advinus Therapeutics has announced that it has discovered a novel molecule - coded GKM-001 - for the treatment of type 2 diabetes
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.